Palvella Therapeutics (PVLA) Q1 2025 earnings summary

Executive summary

• Exceeded enrollment target in Phase 3 SELVA study for QTORIN rapamycin in microcystic lymphatic malformations (mLMs); top-line data expected Q1 2026, with enrollment closing June 2025.

• Phase 2 TOIVA study in cutaneous venous malformations (cVMs) actively enrolling at six sites; top-line data expected Q4 2025.

• Announced plans to unveil two new QTORIN programs in H2 2025, expanding the pipeline to additional mTOR-driven indications.

• Strengthened executive team and IP portfolio, including a fifth U.S. patent extending protection to 2038, and preparing for NDA submission and commercialization.

• Awarded up to $2.6 million in non-dilutive FDA Orphan Products Grant funding for Phase 3 SELVA trial.

Financial highlights

• Cash and cash equivalents were $75.6 million as of March 31, 2025, providing a runway into the second half of 2027.

• Q1 2025 research and development expenses were $4.1 million, up from under $1 million in Q1 2024, driven by clinical trial activity and headcount growth.

• General and administrative expenses were $3.8 million, up from $800,000 year-over-year, reflecting public company costs and increased headcount.

• Net loss for Q1 2025 was $8.2 million ($0.74 per diluted share), compared to $2.7 million ($1.54 per diluted share) in Q1 2024.

• 2025 cash spend is projected at approximately $30 million, with year-end cash expected to be at least $55 million.

Outlook and guidance

• Top-line Phase 3 SELVA data for mLMs expected in Q1 2026; NDA submission planned for H2 2026, targeting approval in Q2 2027.

• Top-line Phase 2 TOIVA data for cVMs expected in Q4 2025.

• Two new QTORIN programs to be announced in H2 2025.

• Cash runway expected to last into H2 2027, supporting current strategic agenda.

• Standalone U.S. commercialization prioritized; ex-U.S. launches may involve partnerships.